In this context, inhibition of galectin-1, similar to other antiangiogenic agents, resulted in transient vessel normalization, as evidenced by vasculature remodeling, increased pericyte coverage of vessels, and T cell infiltration, as well as reduced tumor hypoxia [52,196,350]. The gene discussed is LGALS1; the disease is neoplasm.